Evolva revised earnings guidance for the year of 2016. Based on preliminary, unaudited numbers, 2016 revenues are now expected to come in at between CHF 9-10 million, around a third lower than expected in August. This reduction is a function of two things: a technical milestone in the stevia program, which was expected towards the end of 2016, was not achieved. Evolva product sales increased almost fourfold in 2016 over 2015, a lower rate than projected. The primary reason was that customer conversion takes longer than expected. Despite this the sales trajectory is clearly positive and the customer pipeline continues to improve. The preliminary 2016 end cash position is estimated to be on target at around CHF 47 million.